Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Lancet. Infectious Diseases (Print)

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1473-3099(17)30449-8PMID 28845791
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug-resistant tuberculosis threatens WHO's End-TB strategy.

  2017cited by this paper
• Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis

  2017cited by this paper
• Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis

  2017cited by this paper
• Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study.

  2017cited by this paper
• Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics

  2016cited by this paper
• Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

  2016cited by this paper
• Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.

  2011cited by this paper

• Imipenem pharmacokinetics/pharmacodynamics in preclinical hollow fiber model, dose-finding in virtual patients, and clinical evidence of efficacy for Mycobacterium abscessus lung disease.

  2024cites this paper
• Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development

  2023cites this paper
• Limited sampling strategies for therapeutic drug monitoring of anti-tuberculosis medications: A systematic review of their feasibility and clinical utility.

  2023cites this paper
• Drug hypersensitivity in drug-resistant tuberculosis

  2023cites this paper
• A Review of Clinical Pharmacokinetic and Pharmacodynamic Relationships and Clinical Implications for Drugs Used to Treat Multi-drug Resistant Tuberculosis

  2020cites this paper
• Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study

  2020cites this paper
• Acquired Drug Resistance: Recognizing the Potential of Repurposed Drugs.

  2019cites this paper
• Effects of including variables such as length of stay in a propensity score analysis with costs as outcome.

  2019cites this paper
• Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients

  2018cites this paper
• Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.

  2018cites this paper
• Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.

  2018cites this paper